Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00821366
Other study ID # FEATS
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received January 12, 2009
Last updated February 25, 2009
Start date October 2007
Est. completion date June 2010

Study information

Verified date January 2009
Source Centre for Health Systems Research & Development, University of the Free State
Contact n/a
Is FDA regulated No
Health authority South Africa: Department of Health
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the benefits of ARV treatment to patients, to the family members of patients on ARV treatment, and to communities at large. The study also aims to investigate the impact of a peer adherence support and a nutritional intervention on measures of treatment success. To this end, 648 patients who had commenced ARV treatment in the past month at twelve selected health care facilities will be recruited into the study. In addition, 204 randomly sampled households from the communities served by the twelve selected clinics will be recruited into the study. Trained enumerators will at baseline conduct semi-structured interviews with patients and households. Following the baseline survey, patients recruited into the study will be randomly assigned to one of three groups:

- Patients receiving ARV treatment and the associated support currently provided in the public sector ARV treatment programme.

- Patients receiving (a) plus bi-weekly visits by an experienced ARV patient who has been trained as a peer adherence supporter

- Patients receiving (a) and (b) plus a weekly nutritional supplement in the form of two 400g cans of meatballs and spaghetti in tomato sauce The group of 'comparison' households comprises the fourth group. Trained enumerators will conduct follow-up interviews with all patients and households at approximately six- and at twelve-months respectively. In addition, the ARV coordinator and other providers working in the ARV treatment programme at each of the twelve selected health care facilities will be interviewed by trained enumerators, at baseline and again at six- and at twelve-months. Clinical data will be obtained from patient files at baseline and at completion of the study. Using these data, various outcomes of importance to the study will be compared between the four study groups, using experimental and non-experimental methods.


Description:

The study has three main objectives, each with a set of more specific aims:

Objective 1: Present a broader view of treatment success

In order to achieve this objective, the study aims to:

- Investigate how access to antiretroviral treatment and to nutritional supplementation impacts labour productivity and time allocation of patients and other household members

- Investigate how access to antiretroviral treatment and to nutritional supplementation impacts household welfare

- Investigate how access to antiretroviral treatment and to nutritional supplementation impacts educational and health outcomes for children in households with patients on antiretroviral treatment

Objective 2: Develop a model of the determinants of treatment success

In order to achieve this objective, the study aims to:

- Determine how various individual, household and facility-level characteristics impact adherence to antiretroviral treatment, including access to a disability grant

- Determine how access to a peer adherence supporter and nutritional supplementation impacts adherence to antiretroviral treatment

- Estimate the cost-effectiveness of these interventions in enhancement in adherence, from both a fiscal and a social perspective

Objective 3: Understand the links between treatment and prevention

In order to achieve this objective, the study aims to:

- Determine how access to antiretroviral treatment impacts on the uptake of voluntary counselling and testing among members of households including patients on ARV treatment and among members of households in the general community

- Determine how access to antiretroviral treatment, to a peer adherence supporter and to nutritional supplementation impacts on the sexual behaviour of patients on antiretroviral treatment, their household members, and members of households in the general community

The study aims to investigate effective AIDS treatment and support in settings where free ARV treatment has been introduced already, with issues of scale-up and sustainability as a result representing an important issue. The study therefore is being conducted in twelve phase I ARV assessment sites in the Free State province, i.e. sites where ARV treatment first became available when the ARV treatment programme was launched in the Free State province in 2004/05.

1. Type of study The study is a prospective, cohort study with a patient, household, facility and provider survey component. The study has a social scientific focus, with a clinical component, and comprises two behavioural interventions.

2. Description of experimental design The study is a combination of a group time-series quasi-experimental design and a a variation of a double randomised consent design. The study comprises four groups of households, three of which include patients on ARV treatment (Figure 1). The provision of ARV treatment represents a quasi- or field experiment, while the peer adherence support and nutritional interventions represent a randomised-control experiment executed in accordance with a Zelen-type double randomised consent design. This study design is deemed appropriate given the fact that: blinding is not practicable or possible; the use of classical randomisation and informed consent procedures significantly threatens internal validity; the interventions are highly attractive; the control group receives standard care; the study focuses on a clinically relevant objective(s) and offers important new insights (Kaptchuk, 2001; MacLehose et al, 2001; Rains & Penzien, 2005).

Figure 1: Experimental study design

Group A: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme Sample size: n~216]

Group B: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme PLUS Adherence support provided by a trained peer adherence supporter during twice weekly visits to the patient [Sample size: n~216]

Group C: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme PLUS Adherence support provided by a trained peer adherence supporter during twice weekly visits to the patient PLUS Nutritional supplementation: weekly delivery of two 400g cans of meatballs and spaghetti in tomato sauce by peer adherence supporter [Sample size: n~216]

Group D: Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment [Sample size: n~180]

Sample size estimation:

The sample size calculation for the arms of the study is based on the method proposed by Freedman (1982). The sample size estimation is based on the following assumptions:

- The proportion of people showing an improvement in a specific outcome, are compared across two arms of the study at a time.

- Attrition in the control group of comparison households is assumed to be minimal or none (since there is no ARV patient in the household), while attrition in the intervention arms (where ARV treatment is considered an intervention) is assumed to be much higher, given a reported mortality of 10% among ARV patients in the first months of treatment (Free State Department of Health, 2006).

- The required sample sizes for a 4-equal-arms-at-end-of-study design were calculated taking into account the attrition rate of 17% in the three intervention groups and a ratio of 1 for the treatment: control arms at the end of the study is expected.

- Assuming a two-tailed test with Type I error of 5%, Type II error of 10%, and at least 17% improvement in any outcome.

The affordable sample size was 801 households with 177 for the control arm and 208 for each of the intervention arms. This sample is expected to yield statistically significant results for the analysis of all measures contemplated. Although the statistical power of the study design with this sample size can be considered good the sample size was rounded up to ~828 households, with ~180 households in the control arm and ~216 households in each of the intervention arms. This was done to represent multiples of 12 since the study will be conducted in 12 facilities.

3. Method of randomisation From among the ~648 ARV patients recruited into the study [~54/study site], individual patients will be assigned randomly to the control group [Group A; n~216] and to the two experimental arms of the study [Group B & C; n~216 each], using the relevant random sampling selection commands in version 10 of the Stata software programme.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 648
Est. completion date June 2010
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- HIV-positive

- Eligible for public sector ARV treatment (CD4<200 and/or WHO stage 4)

- Commenced ARV treatment in past 4 weeks

- Patient resident in town/village where ART clinic located

Exclusion Criteria:

- HIV-negative

- Not eligible for public sector ARV treatment

- Had not commenced ARV treatment

- Commenced ARV treatment longer than one month ago

- Patient not resident in town/village where ART clinic

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
ARV peer adherence support (PAS)
Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
Dietary Supplement:
Nutritional support
Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
Drug:
ARV treatment
Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme

Locations

Country Name City State
South Africa Batho clinic Bloemfontein Free State
South Africa MUCPP clinic Bloemfontein Free State
South Africa Tswelepele clinic Bloemfontein Free State
South Africa Refengkhotso clinic Deneysville Free State
South Africa Tshiame clinic Harrismith Free State
South Africa Itumeleng clinic Jagersfontein Free State
South Africa Phomolong clinic Phomolong Free State
South Africa Namahali clinic Phuthaditjaba Free State
South Africa Tseki clinic Phuthaditjaba Free State
South Africa Zamdela clinic Sasolburg Free State
South Africa Matjhabeng clinic Welkom Free State
South Africa Welkom clinic Welkom Free State

Sponsors (3)

Lead Sponsor Collaborator
Centre for Health Systems Research & Development, University of the Free State Bank-Netherlands Partnership Programme (BNPP), World Bank

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary CD4 count 6-monthly No
Primary RNA viral load 6-monthly No
Primary Haemoglobin 6-monthly No
Primary self-reported adherence (CASE index) 6-monthly No
Primary health-related quality of life (EQ-5D/EQ-VAS) 6-monthly
Primary anthropometrics monthly to 6-monthly No
Primary food security (USDA scales) 6-monthly No
Primary time allocation/physical activity levels 6-monthly No
Primary household welfare 6-monthly No
Secondary mental health (HADS/MHI scales) 6-monthly No
Secondary labour force participation 6-monthly No
Secondary employment status 6-monthly No
Secondary self-reported sexual behaviour 6-monthly No
Secondary school attendance/performance 6-monthly No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2